Immunotherapy Drugs: Global Markets Through 2019, 2020, and 2021-2025
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins.
The monoclonal antibodies segment accounted for the largest share of the global market for immunotherapy drugs in 2019. This large share can be attributed to several factors including their high specificity and fewer side-effects; the increasing focus on personalized medicines; initiatives by industry players; and the growing target disease incidence and patient pool. In 2019, the market for monoclonal antibodies was $106.8 billion.
The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.
Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and the rest of the world (RoW).
The report includes:
An overview of the global market for immunotherapy drugs
Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) though 2025
Evaluation of current market size and forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting the market growth
Description of immunotherapy, combination immunotherapy and discussion on how it targets cell-mediated adaptive immunity
Market share analysis of the immunotherapy drugs based on type of drug, therapy area, end-user and region
Information on personalized treatment paradigm, details of clinically significant types of cancers and discussion on the future of immunotherapy in cancer
Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and novel targeted approaches for immunotherapy
Discussion on fine-tuning versus boosting cancer immunity and early versus advanced-stage cancer immunotherapy
Market share analysis of the major players in the industry, and discussion on their technological strengths and weakness, and innovative marketing practices
Comprehensive company profiles of major players of the industry, including Amgen Inc., Bayer AG, Johnson & Johnson, Novartis AG and Pfizer Inc.
Key Topics Covered
Chapter 1 Introduction
Study Goals and Objectives
Scope of Report
Methodology
Market Estimates
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Vs. Boosting Cancer Immunity
Early Vs. Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers
Lung Cancer
Breast Cancer
Colorectal Cancer
Stomach Cancer
Leukemia
Future of Immunotherapy in Cancer
Infectious Diseases
Immunotherapy against Autoimmune Disorders
Immunotherapies against Infectious Diseases
Biologics as Autoimmune Disorder Therapies
Trends in Autoimmune Disorder Therapies
Types of Immunotherapies
Checkpoint Inhibitors
Unmet Medical Needs
New Biomarkers to Stratify Patients
Relapse/Refractory Patients
Treatment Efficacy and Tolerability
Innovative Strategies
Novel Targeted Approaches
Monoclonal Antibodies
Interleukins
Interferons
Chapter 4 Market Dynamics
Strengths of Immunotherapy Market
Growing Aging Population
Rising Incidence of Diseases
Patent Expirations
Growing Pipeline
Drive to Reduce Costs
Government Incentives
Collaborations and Partnerships
Mergers and Acquisitions
Weaknesses of the Immunotherapy Market
Manufacturing Process
Process Definition and Testing and Validation
Lack of Skilled Personnel
Regulatory Guidelines
Patent Litigation
Threats to Immunotherapy Market
Unpredictable Regulatory Landscape
Prescriptions by Medical Practitioners/Pharmacies
Competition
Opportunities in the Immunotherapy Market
Emerging Markets
Technological Innovation and Improved Process Knowledge
Pricing
Chapter 5 Impact of COVID-19 on the Pharmaceutical Industry
Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
Changes to R&D
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in the Pharmaceutical Industry
Changes in Consumption Trends in Health-related Products
Chapter 6 Market Breakdown by Product Type
Overview
Monoclonal Antibodies
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Checkpoint Inhibitors
Pembrolizumab
Companion Diagnostic
Clinical Trial Program
Forecast for Pembrolizumab
Nivolumab (Opdivo)
Companion Diagnostic
Clinical Trial Program
Forecast for Nivolumab
Atezolizumab (Tecentriq)
Companion Diagnostic
Clinical Trial Program
Forecast for Atezolizumab
Avelumab (Bavencio)
Companion Diagnostic
Clinical Trial Program
Forecast for Avelumab
Durvalumab (Imfinzi)
Companion Diagnostic
Clinical Trial Program
Durvalumab Forecasts
Yervoy (Ipilimumab)
Market by Region
Market Revenue
Market Share
Interferons and Interleukins
Market Revenue
Market by Region
Market by Disease Area
Chapter 7 Market Breakdown by Region
Market Overview and Discussion
North America
United States
Canada
Europe
Asia-Pacific
China
Japan
Rest of the World
Chapter 8 Company Profiles
Abbvie Inc.
Amgen Inc.
AstraZeneca
Bayer AG
Bristol Myers Squibb
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Viatris Inc. (Formerly Mylan)
Novartis AG
Pfizer Inc.
Vertex Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/s0o82p
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900